Quoin Pharmaceuticals
Clinical trials sponsored by Quoin Pharmaceuticals, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a lotion calm the severe skin symptoms of netherton syndrome? Results expected Dec 2026 (estimated)
- Can a skin lotion tame the symptoms of a rare genetic disease? Results expected Dec 2026 (estimated)
- New lotion shows promise for rare skin disorder Results expected Jan 2027 (estimated)
-
Can a skin lotion tame the symptoms of a rare genetic disease?
Disease control Recruiting nowThis trial tests whether QRX003, a lotion applied to the skin, can reduce the redness, scaling, and itch caused by Netherton syndrome, a rare genetic condition. Participants apply the lotion twice daily for 3 months and visit the clinic every 4 to 6 weeks for checkups. The study …
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a lotion calm the severe skin symptoms of netherton syndrome?
Disease control Recruiting nowThis trial tests whether QRX003 lotion, applied to the skin, can safely reduce the severity of Netherton syndrome, a rare genetic condition causing red, scaly skin and intense itching. Researchers will enroll about 20 people aged 14 and older who have the condition. Participants …
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New lotion shows promise for rare skin disorder
Disease control Recruiting nowThis study tests a lotion called QRX003 in people with Netherton Syndrome, a rare genetic skin condition. About 16 participants aged 4 and older will apply the lotion twice daily for 12 weeks. Researchers will check if it improves skin appearance and reduces itching.
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC